Zydus Lifesciences Hits 52-Week High After US FDA Update

Zydus Lifesciences Ltd has been in focus today after the company announced that the US FDA inspection at its New Jersey office concluded with nil observations. The inspection covered the company’s pharmacovigilance and post-marketing surveillance systems and was conducted from September 22 to September 25, 2026. The stock touched a fresh 52-week high of ₹1,228.60 during today’s trading session. The company’s latest Q1 FY27 results reported consolidated revenue of ₹8,017 crore, up 21.96% YoY. Net profit attributable to owners stood at ₹939.8 crore, down 35.93% YoY. The combination of the latest regulatory update and the stock’s fresh 52-week high keeps Zydus Lifesciences in focus for market participants.